Dr. West to Deliver Presentation on Applying AI to Stem Cell Biology and
Participate in Roundtable Discussion
ALAMEDA, Calif.--(BUSINESS WIRE)--May 8, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Co-Chief Executive Officer Michael D.
West, Ph.D. will present at Terrapinn’s World
Advanced Therapies & Regenerative Medicine Congress, May 17-19
Design Centre in London.
Titled “Applying Artificial Intelligence to Stem Cell Biology,” Dr.
West’s presentation is scheduled for Friday, May 19 at 11:40 a.m. BST.
Expanding on a presentation
Dr. West gave last year, it will provide an update on deep learning
algorithms and their potential to unlock mechanisms of tissue
regeneration for applications in age-related disease, and how these
insights will dovetail with BioTime’s recently-announced
subsidiary, AgeX Therapeutics.
Additionally, on the first day of the conference, Wednesday, May 17, Dr.
West will present at a plenary roundtable discussion with seven other
senior-level executives, including Jane Lebkowski, Ph.D., Chief
Scientific Officer and President of Research & Development at BioTime
affiliate company Asterias
Biotherapeutics. Titled “Process Development & Manufacturing Focus,”
the session will begin at 11:40 a.m. BST.
More information about the World Advanced Therapies & Regenerative
Medicine Congress is available here.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime
founded and which, until recently, were majority-owned consolidated
subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005408/en/
Source: BioTime, Inc.
EVC Group, Inc.
Brian Moore, 310-770-0389
Bill Douglass, 646-504-0890